Pharmaceutical firm Strides Arcolab holds a 12% stake in the biosimilar developer after investing $9m in 2014.

The pharmaceutical firm's Lilly Asia Ventures unit is co-investing in the T-cell technology developer with University of Pennsylvania.

The DNA sequencing technology developer raises $9.25m from Utah University's Arup Laboratories and others to further develop its product and increase sales and marketing.

The pharmaceutical firm's Lilly Asia Ventures unit is co-investing in the T-cell technology developer with University of Pennsylvania.

Lodo Therapeutics has been launched by investment firm Accelerator Corporation with series A capital from investors including AbbVie, Eli Lilly, Wuxi PharmaTech, Pfizer, IBM and Johnson & Johnson.

Switzerland-based Novimmune, which counts Fracht as an investor, has now raised almost $230m and is working on cancer, inflammatory and autoimmune disease treatments.

General Electric and RELX were among the investors that supplied the risk management software provider with capital as it spun out from Healthline Networks.

WuXi Healthcare Ventures and corporate-backed Deerfield Management are among the investors in the gene control drug developer's series C round.

Lodo Therapeutics has been launched by investment firm Accelerator Corporation with series A capital from investors including AbbVie, Eli Lilly, Wuxi PharmaTech, Pfizer, IBM and Johnson & Johnson.